Evidence map›Paper›PMID 31216425›Full record

ReviewMolecular and cellular neurosciences2019

Mitochondrial dynamics and transport in Alzheimer's disease.

Padraig J Flannery, Eugenia Trushina

Abstract readReview
In one paragraph

Review in Molecular and cellular neurosciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Molecular mechanisms of mitochondrial quality control.Translational neurodegeneration · 2025
    Review
  17. New Approaches to the Treatment of Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  18. Article
  19. Article
  20. Aging · 2025
    Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Padraig J FlanneryDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Eugenia TrushinaDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: trushina.eugenia@mayo.edu.

Funding

Mitochondrial Complex I as a Target for Neuroprotection in ADRF1AG055549 · NIA · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2017 to 2025
$7.0M
AMP-Kinase as a target for neuroprotection in ADRF1AG062135 · NIA · UNIVERSITY OF MINNESOTA · PI LEE, MICHAEL K, TRUSHINA, EUGENIA · 2019 to 2019
$3.2M
Small molecule mitochondria-targeted therapeutics for Huntingtons DiseaseR01NS107265 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2018 to 2021
$2.2M
Small Molecule Mitochondria-Targeted Therapeutics for AD (Supplement)UH3NS113776 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2022 to 2022
$1.1M
NIA NIH HHS R01 AG062135NIA NIH HHS RF1 AG055549NIA NIH HHS RF1 AG062135NINDS NIH HHS R01 NS107265NINDS NIH HHS UH3 NS113776
6 · The paper itself

Abstract

Mitochondrial dysfunction is now recognized as a contributing factor to the early pathology of multiple human conditions including neurodegenerative diseases. Mitochondria are signaling organelles with a multitude of functions ranging from energy production to a regulation of cellular metabolism, energy homeostasis, stress response, and cell fate. The success of these complex processes critically depends on the fidelity of mitochondrial dynamics that include the ability of mitochondria to change shape and location in the cell, which is essential for the maintenance of proper function and quality control, particularly in polarized cells such as neurons. This review highlights several aspects of alterations in mitochondrial dynamics in Alzheimer's disease, which may contribute to the etiology of this debilitating condition. We also discuss therapeutic strategies to improve mitochondrial dynamics and function that may provide an alternative approach to failed amyloid-directed interventions.

Indexed as

Axonal TransportMitochondrial DynamicsAlzheimer DiseaseAnimalsHumansNeuronsAlzheimer's diseaseAxonal traffickingFissionFusionMitochondriaMitochondria-targeted therapeuticsMitophagy

Identifiers

PMID31216425
PMCPMC6614006

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.